Stockreport

enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants

enGene Holdings Inc.  (ENGN) 
PDF BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today anno [Read more]